Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
09 Jan 2024
09 Jan 2024
Historique:
received:
15
10
2023
accepted:
21
12
2023
revised:
19
12
2023
medline:
10
1
2024
pubmed:
10
1
2024
entrez:
10
1
2024
Statut:
aheadofprint
Résumé
Therapy-related myeloid neoplasms (t-MN), either myelodysplastic neoplasms (t-MDS) or acute myeloid leukemias (t-AML), have a poor prognosis and allogeneic haematopoietic cell transplantation (allo-HCT) represents the only curative option. In this multicenter, registry-based study, we analyzed outcomes of 378 patients undergoing first allo-HCT between 2006-2017 for t-MN arising secondary to lymphoma treatment. Median age was 58 years at allo-HCT; 222 (59%) had a diagnosis of t-MDS and 156 (41%) of t-AML, respectively. At the time of allo-HCT, 46% of t-MN cases were reported as in complete remission (CR) and 15% of lymphomas were recorded as not in remission. A reduced intensity conditioning regimen was used in 70% of cases. For the entire cohort, 5-year OS, and t-MN PFS, relapse incidence and NRM were 32%, 28%, 35% and 37%, respectively. In multivariable analysis, undergoing allo-HCT with t-MN not in CR and older age were associated with significantly worse OS, PFS and NRM. At 5 years post allo-HCT, the relapse incidence of lymphoma was low at 3%, while the rate of secondary malignancies was 8%. This analysis shows the curative potential of allo-HCT for patients with t-MN arising secondary to lymphoma treatment in approximately a third of patients.
Identifiants
pubmed: 38195984
doi: 10.1038/s41409-023-02193-z
pii: 10.1038/s41409-023-02193-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.
doi: 10.1182/blood-2016-03-643544
pubmed: 27069254
Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345–77.
doi: 10.1182/blood.2022016867
pubmed: 35797463
Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka H-M, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200–28.
doi: 10.1182/blood.2022015850
pubmed: 35767897
pmcid: 9479031
Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36:1703–19.
doi: 10.1038/s41375-022-01613-1
pubmed: 35732831
pmcid: 9252913
Snowden JA, Sánchez-Ortega I, Corbacioglu S, Basak GW, Chabannon C, de la Camara R, et al. Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplant. 2022;57:1217–39.
doi: 10.1038/s41409-022-01691-w
pubmed: 35589997
pmcid: 9119216
Morton LM, Curtis RE, Linet MS, Schonfeld SJ, Advani PG, Dalal NH, et al. Trends in risk for therapy-related myelodysplastic syndrome/acute myeloid leukemia after initial chemo/immunotherapy for common and rare lymphoid neoplasms, 2000–2018. eClinicalMedicine. 2023;61:102060.
doi: 10.1016/j.eclinm.2023.102060
pubmed: 37457112
pmcid: 10344829
Eichenauer DA, Thielen I, Haverkamp H, Franklin J, Behringer K, Halbsguth T, et al. Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood. 2014;123:1658–64.
doi: 10.1182/blood-2013-07-512657
pubmed: 24478403
Radivoyevitch T, Dean RM, Shaw BE, Brazauskas R, Tecca HR, Molenaar RJ, et al. Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. Leuk Res. 2018;74:130–6.
doi: 10.1016/j.leukres.2018.07.016
pubmed: 30055822
pmcid: 6219911
Bachiashvili K, Francisco L, Chen Y, Bosworth A, Forman SJ, Bhatia R, et al. Peripheral blood parameter abnormalities precede therapy‐related myeloid neoplasms after autologous transplantation for lymphoma. Cancer. 2022;128:1392–401.
doi: 10.1002/cncr.34072
pubmed: 34962652
Joelsson J, Wästerlid T, Rosenquist R, Jakobsen LH, El-Galaly TC, Smedby KE, et al. Incidence and time trends of second primary malignancies after non-Hodgkin lymphoma: a Swedish population-based study. Blood Adv. 2022;6:2657–66.
doi: 10.1182/bloodadvances.2021006369
pubmed: 35042239
pmcid: 9043935
Moreno Berggren D, Garelius H, Willner Hjelm P, Nilsson L, Rasmussen B, Weibull CE, et al. Therapy-related MDS dissected based on primary disease and treatment—a nationwide perspective. Leukemia. 2023;37:1103–12.
doi: 10.1038/s41375-023-01864-6
pubmed: 36928008
pmcid: 10169633
Alkhateeb HB, Mohty R, Greipp P, Bansal R, Hathcock M, Rosenthal A, et al. Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for non-hodgkin lymphoma. Blood Cancer J. 2022;12:113.
doi: 10.1038/s41408-022-00707-4
pubmed: 35882844
pmcid: 9325766
Carreras E, Dufour C, Mohty M, Kröger N, editors. The EBMT handbook: hematopoietic stem cell transplantation and cellular therapies. Cham: Springer International Publishing; 2019. https://doi.org/10.1007/978-3-030-02278-5 .
Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2009;15:1628–33.
doi: 10.1016/j.bbmt.2009.07.004
Robin M, De Wreede LC, Schroeder T, Stölzel F, Kröger N, Koster L, et al. Primary cancer matters in therapy-related myeloid neoplasm patients receiving allogeneic hematopoietic cell transplantation: a Study From the Chronic Malignancies Working Party of the EBMT. HemaSphere. 2023;7:e851.
doi: 10.1097/HS9.0000000000000851
pubmed: 36891455
pmcid: 9988287
Nabergoj M, Mauff K, Beelen D, Ganser A, Kröger N, Stölzel F, et al. Allogeneic hematopoietic cell transplantation in patients with therapy-related myeloid neoplasm after breast cancer: a study of the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplant. 2022;57:1072–8.
doi: 10.1038/s41409-022-01686-7
pubmed: 35459878
Robin M, Wang J, Koster L, Beelen DW, Bornhäuser M, Kroeger N, et al. Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in patients with therapy-related myeloid neoplasm: a study from the Chronic Malignancies Working Party of the EBMT. Blood. 2019;134:45–5.
doi: 10.1182/blood-2019-124765
Gatwood KS, Labopin M, Savani BN, Finke J, Socie G, Beelen D, et al. Transplant outcomes for patients with therapy-related acute myeloid leukemia with prior lymphoid malignancy: an ALWP of EBMT study. Bone Marrow Transplant. 2020;55:224–32.
doi: 10.1038/s41409-019-0673-3
pubmed: 31527819
Wenge DV, Wethmar K, Mikesch J-H, Reicherts C, Schliemann C, Mesters R, et al. Allogeneic hematopoietic stem cell transplantation for therapy-related myeloid neoplasms following treatment of a lymphoid malignancy. Leuk Lymphoma. 2021;62:1930–9.
doi: 10.1080/10428194.2021.1894645
pubmed: 33779471
Jaimes-Albornoz D, Mannone L, Nguyen-Quoc S, Chalandon Y, Chevallier P, Mohty M, et al. Allogeneic stem cell transplantation in therapy-related myelodysplasia after autologous transplantation for lymphoma: a retrospective study of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2019;25:2366–74.
doi: 10.1016/j.bbmt.2019.07.013
pubmed: 31326611
Kroger N, Brand R, van Biezen A, Zander A, Dierlamm J, Niederwieser D, et al. Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation. Haematologica. 2009;94:542–9.
doi: 10.3324/haematol.2008.000927
pubmed: 19278968
pmcid: 2663618
Arai S, Sahaf B, Narasimhan B, Chen GL, Jones CD, Lowsky R, et al. Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Blood. 2012;119:6145–54.
doi: 10.1182/blood-2011-12-395970
pubmed: 22563089
pmcid: 3383022
Metheny L, Callander NS, Hall AC, Zhang M-J, Bo-Subait K, Wang H-L, et al. Allogeneic Transplantation to treat therapy-related myelodysplastic syndrome and acute myelogenous leukemia in adults. Transplant Cell Ther. 2021. https://doi.org/10.1016/j.jtct.2021.08.010 .
Lee CJ, Labopin M, Beelen D, Finke J, Blaise D, Ganser A, et al. Comparative outcomes of myeloablative and reduced‐intensity conditioning allogeneic hematopoietic cell transplantation for therapy‐related acute myeloid leukemia with prior solid tumor: A report from the acute leukemia working party of the European society for blood and bone marrow transplantation. Am J Hematol. 2019;94:431–8.
doi: 10.1002/ajh.25395
pubmed: 30597620
Lawless S, Morris C, Eikema D-J, Kostner L, Stoelzel F, Kröger N, et al. Outcomes of allogeneic haematopoietic stem cell transplantation for therapy-related myeloid neoplasms following treatment for myeloma. Blood. 2022;140:4884–5.
doi: 10.1182/blood-2022-169326
Minetto P, Guolo F, Clavio M, Kunkl A, Colombo N, Carminati E, et al. Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information. Br J Haematol. 2019;184:457–60.
doi: 10.1111/bjh.15106
pubmed: 29359798
Press RD, Eickelberg G, Froman A, Yang F, Stentz A, Flatley EM, et al. Next‐generation sequencing‐defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse. Am J Hematol. 2019;94:902–12.
doi: 10.1002/ajh.25514
pubmed: 31124175
Hoffmann AP, Besch AL, Othus M, Morsink LM, Wood BL, Mielcarek M, et al. Early achievement of measurable residual disease (MRD)-negative complete remission as predictor of outcome after myeloablative allogeneic hematopoietic cell transplantation in acute myeloid leukemia. Bone Marrow Transplant. 2020;55:669–72.
doi: 10.1038/s41409-019-0739-2
pubmed: 31685932
Caballero-Velázquez T, Pérez-López O, Yeguas Bermejo A, Rodríguez Arbolí E, Colado Varela E, Sempere Talens A, et al. Prognostic value of measurable residual disease in patients with AML undergoing HSCT: a multicenter study. Cancers. 2023;15:1609.
doi: 10.3390/cancers15051609
pubmed: 36900400
pmcid: 10000405